Overcoming natural Wnt inhibition to optimize therapy

Affiliations

¹ St Vincent's Institute of Medical Research and The University of Melbourne Department of Medicine, St Vincent's Hospital, Fitzroy, Victoria, Australia. nsims@svi.edu.au.

Review

Natalie A Sims. Nat Rev Rheumatol. 2019 Feb.

. 2019 Feb;15(2):67-68.

doi: 10.1038/s41584-018-0153-y.

¹ St Vincent's Institute of Medical Research and The University of Melbourne Department of Medicine, St Vincent's Hospital, Fitzroy, Victoria, Australia. nsims@svi.edu.au.

No abstract available

References

1. Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016). - DOI
1. Holdsworth, G. et al. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 107, 93–103 (2018). - DOI
1. Witcher, P. C. et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI Insight 3, 98673 (2018). - DOI
1. Luther, J. et al. Wnt1 is an Lrp5-independent bone-anabolic Wnt ligand. Sci. Transl Med. 10, eaau7137 (2018). - DOI
1. Weske, S. et al. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat. Med. 24, 667–678 (2018). - DOI